Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels

Journal of Analytical Toxicology

Volumn 31, Issue 5, 2007, Pages 254-264

  Reis, M ^a   Aamo, T ^b   Ahlner, J ^c   Druid, H ^d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c Swedish National Board of Forensic Medicine   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; AUTOPSY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INTOXICATION; DRUG MONITORING; FEMALE; HEALTH SURVEY; HUMAN; MALE;

EID: 34250364501     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/31.5.254     Document Type: Article

References (52)

1. R.C. Baselt, J.A. Wright, and R.H. Cravey. Therapeutic and toxic concentrations of more than 100 toxicologically significant drugs in blood, plasma, or serum: a tabulation. Clin. Chem. 21: 44-62 (1975).
2. A.H. Stead and A.C. Moffat. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum. Toxicol. 2: 437-464 (1983).
3. D.J. Pounder and G.R. Jones. Post-mortem drug redistribution - a toxicological nightmare. Forensic Sci. Int. 45: 253-263 (1990).
4. T. Hilberg, S. Rogde, and J. Mørland. Postmortem drug redistribution - human cases related to results in experimental animals. J. Forensic Sci. 44: 3-9 (1999).
5. F.C. Kugelberg, H. Druid, B. Carlsson, J. Ahlner, and F. Bengtsson. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. J. Anal. Toxicol. 28: 631-637 (2004)
6. P. De Paepe, F.M. Belpaire, M.T. Rosseel, and W.A. Buylaert. The influence of hemorrhagic shock on the pharmacokinetics and the analgesic effect of morphine in the rat. Fundam. Clin. Pharmacol. 12: 624-630 (1998).
7. F.C. Kugelberg, K. Alkass, M. Kingbäck, B. Carlsson, and H. Druid. Influence of blood loss on the pharmacokinetics of citalopram. Forensic Sci. Int. 161: 163-168 (2006).
8. B.S. Levine, R.V. Blanke, and J.C. Valentour. Postmortem stability of barbiturates in blood and tissues. J. Forensic Sci. 29: 131-138 (1984).
9. H.M. Stevens. The stability of some drugs and poisons in putrefying human liver tissues. J. Forensic Sci. Soc. 24: 577-589 (1984).
10. P. Holmgren, H. Druid, A. Holmgren, and J. Ahlner. Stability of drugs in stored postmortem femoral blood and vitreous humor. J. Forensic Sci. 49: 820-825 (2004).
11. K.A. Hadidi and J.S. Oliver. Stability of morphine and buprenorphine in whole blood. Int. J. Legal Med. 111: 165-167 (1998).
12. M.D. Robertson and O.H. Drummer. Stability of nitrobenzodiazepines in postmortem blood. J. Forensic Sci. 43: 5-8 (1998).
13. H. Druid, P. Holmgren, B. Carlsson, and J. Ahlner. Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results. Forensic Sci. Int. 99: 25-34 (1999).
14. A. Koski, E. Vuori, and I. Ojanperä. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int. J. Legal Med. 119: 344-348 (2005).
15. A. Koski, J. Sistonen, I. Ojanperä, M. Gergov, E. Vuori, and A. Sajantila. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci. Int. 158: 177-183 (2006).
16. H. Druid, P. Holmgren, and P. Löwenhielm. Computer-assisted systems for forensic pathology and forensic toxicology. J. Forensic Sci. 41: 830-836 (1996).
17. H. Druid and P. Holmgren. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J. Forensic Sci. 42: 79-87 (1997).
18. A.F. Schatzberg and C.B. Nemeroff, Eds. Essentials of Clinical Psychopharmacology. American Psychiatric Publishing, Washington, D.C., 2001.
19. M. Öström, A. Eriksson, J. Thorson, and O. Spigset. Fatal overdose with citalopram. Lancet 348: 339-340 (1996).
20. L. Grundemar, B. Wohlfart, C. Lagerstedt, F. Bengtsson, and G. Eklundh. Symptoms and signs of severe citalopram overdose. Lancet 349: 1602 (1997).
21. WHO. International Classification of Diseases, 9th revision (ICD-9), WHO, Geneva, Switzerland, 1979.
22. Swedish Medical Products Agency. Uppsala, Sweden, 2006.
23. National Corporation of Swedish Pharmacies, 2006.
24. K. Worm, C. Dragsholt, K. Simonsen, and B. Kringsholm. Citalopram concentrations in samples from autopsies and living persons. Int. J. Legal Med. 111: 188-190 (1998).
25. J.T. Barbey and S.P. Roose. SSRI safety in overdose. J. Clin. Psychiatry 59 Suppl15: 42-48 (1998).
26. H. Druid and P. Holmgren. Compilations of therapeutic, toxic, and fatal concentrations of drugs. J. Toxicol. Clin. Toxicol. 36: 133-134 (1998).
27. M. Reis, J. Lundmark, and F. Bengtsson. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther. Drug Monit. 25: 183-191 (2003).
28. M. Reis, A. Åberg-Wistedt, H. Ågren, P. Hoglund, A.C. Åkerblad, and F. Bengtsson. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum. Psychopharmacol. 19: 283-291 (2004).
29. M. Reis, J. Prochazka, A. Sitsen, J. Ahlner, and F. Bengtsson. Inter-and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther. Drug Monit. 27: 469-477 (2005).
30. M. Linnoila, F. Dorrity, Jr., and K. Jobson. Plasma and erythrocyte levels of tricyclic antidepressants in depressed patients. Am. J. Psychiatry 135: 557-561 (1978).
31. Z. Fisar, K. Fuksova, J. Sikora, L. Kalisova, M. Velenovska, and M. Novotna. Distribution of antidepressants between plasma and red blood cells. Neuro. Endocrinol. Lett. 27: 307-313 (2006).
32. F.S. Apple. Postmortem tricyclic antidepressant concentrations: assessing cause of death using parent drug to metabolite ratio. J. Anal. Toxicol. 13: 197-198 (1989).
33. C. Hiemke and S. Härtter. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 85: 11-28 (2000).
34. L. Ereshefsky, C. Riesenman, and Y.W. Lam. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin. Pharmacokinet. 29: 10-19 (1995).
35. M. Eichelbaum, N. Spannbrucker, B. Steincke, and H.J. Dengler. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16: 183-187 (1979).
36. L. Bertilsson, M. Eichelbaum, B. Mellstrom, J. Sawe, H.U. Schulz, and F. Sjöqvist. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci. 27: 1673-1677 (1980).
37. M.L. Dahl and L. Bertilsson. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3: 61-70 (1993).
38. K. Brøsen. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59: 5-12 (2004).
39. P. Holmgren, B. Carlsson, A.L. Zackrisson, B. Lindblom, M.L. Dahl, M.G. Scordo, H. Druid, and J. Ahlner. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYP2D6 and CYP2C19. J. Anal. Toxicol. 28: 94-104 (2004).
40. S. Cheeta, F. Schifano, A. Oyefeso, L. Webb, and A.H. Ghodse. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br. J. Psychiatry 184: 41-47 (2004).
41. P. Baumann, J.W. Meyer, M. Amey, D. Baettig, C. Bryois, M. Jonzier-Perey, L. Koeb, C. Monney, and B. Woggon. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit. 14: 1-8 (1992).
42. M. Gex-Fabry, A.E. Balant-Gorgia, L.P. Balant, and G. Garrone. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin. Pharmacokinet. 19: 241-255 (1990).
43. J. Lundmark, M. Reis, and F. Bengtsson. Serum concentrations of fluoxetine in the clinical treatment setting. Ther. Drug Monit. 23: 139-147 (2001).
44. O. Spigset, K. Granberg, S. Hägg, E. Söderstrom, and R. Dahlqvist. Non-linear fluvoxamine disposition. Br. J. Clin. Pharmacol. 45: 257-263 (1998).
45. F.R. Sallee and B.G. Pollock. Clinical pharmacokinetics of imipramine and desipramine. Clin. Pharmacokinet. 18: 346-364 (1990).
46. L. Firkusny and C.H. Gleiter. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br. J. Clin. Pharmacol. 37: 383-388 (1994).
47. K. Otani, H. Sasa, S. Kaneko, T. Kondo, and Y. Fukushima. Steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin. Ther. Drug Monit. 15: 113-117 (1993).
48. B. Fulton and P. Benfield. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 52: 450-474 (1996).
49. M. Åsberg, B. Cronholm, F. Sjöqvist, and D. Tuck. Relationship between plasma level and therapeutic effect of nortriptyline. Br. Med. J. 3: 331-334 (1971).
50. J. Lundmark, M. Reis, and F. Bengtsson. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther. Drug Monit. 22: 446-454 (2000).
51. J. Kirchheiner, G. Muller, I. Meineke, K.D. Wernecke, I. Roots, and J. Brockmoller. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J. Clin. Psychopharmacol. 23: 459-466 (2003).
52. M. Reis, J. Lundmark, H. Björk, and F. Bengtsson. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther. Drug Monit. 24: 545-553 (2002).